Shire PLC is expanding its hematology business with the acquisition of FerroKin Biosciences, Inc., a San Francisco biotech with an iron chelator in Phase II development. The company announced the acquisition March 15 for an upfront payment of $100 million and potential post-closing milestones of $225 million.
The acquisition announcement comes one day after Shire said it has withdrawn its U.S. BLA for Replagal (agalsidase alfa) for...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?